MCID: CRH001
MIFTS: 74

Crohn's Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Crohn's Disease

MalaCards integrated aliases for Crohn's Disease:

Name: Crohn's Disease 12 74 52 25 42 15 37 17
Crohn Disease 12 25 15 71
Pediatric Crohn's Disease 12 52 71
Enteritis 52 54 71
Crohn's Disease of Large Bowel 12 71
Granulomatous Colitis 12 52
Ileitis 52 71
Pediatric Onset Crohn's Disease 52
Crohn's Disease, Pediatric 52
Crohn's Disease of Colon 12
Enteritis, Granulomatous 25
Granulomatous Enteritis 52
Colitis, Granulomatous 25
Enteritis, Regional 25
Regional Enteritis 71
Crohn's Enteritis 25

Classifications:



External Ids:

Disease Ontology 12 DOID:8778
ICD9CM 34 555.1
MeSH 43 D003424
SNOMED-CT 67 50440006 7620006
UMLS 71 C0010346 C0014335 C0020877 more

Summaries for Crohn's Disease

Genetics Home Reference : 25 Crohn disease is a complex, long-lasting (chronic) disorder that primarily affects the digestive system. This condition involves an abnormal immune response that causes excess inflammation. It most often affects the intestinal walls, particularly in the lower part of the small intestine (the ileum) and portions of the large intestine (the colon). However, inflammation can occur in any part of the digestive system, from the mouth to the anus. The inflamed tissues become thick and swollen, and the inner surfaces of the digestive system may develop open sores (ulcers). Crohn disease most commonly appears in a person's late teens or twenties, although the disease can begin at any age. Signs and symptoms tend to flare up multiple times throughout life. The most common features of this condition are persistent diarrhea, abdominal pain and cramping, loss of appetite, weight loss, and fever. Some people with Crohn disease have blood in the stool from inflamed tissues in the intestine; over time, chronic bleeding can lead to a low number of red blood cells (anemia). In some cases, Crohn disease can also cause inflammation affecting the joints, eyes, or skin. Intestinal blockage is a common complication of Crohn disease. Blockages are caused by swelling or a buildup of scar tissue in the intestinal walls. Some affected individuals also develop fistulae, which are abnormal connections between the intestine and other tissues. Fistulae occur when ulcers break through the intestinal wall and passages form between loops of the intestine or between the intestine and nearby structures (such as the bladder, vagina, or skin). Crohn disease is one common form of inflammatory bowel disease (IBD). Another type of IBD, ulcerative colitis, also causes chronic inflammation of the intestinal lining. Unlike Crohn disease, which can affect any part of the digestive system, ulcerative colitis typically causes inflammation only in the colon.

MalaCards based summary : Crohn's Disease, also known as crohn disease, is related to ileocolitis and inflammatory bowel disease 1, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Crohn's Disease is ENSG00000278769 (), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Tocopherol and Prucalopride have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An intestinal disease that involves inflammation located in intestine.

NIH Rare Diseases : 52 Crohn's disease is a type of inflammatory bowel disease (IBD) , the general name for conditions that cause inflammation in the gastrointestinal (GI) tract. Common signs and symptoms include abdominal pain and cramping, diarrhea, and weight loss. Other general symptoms include feeling tired, nausea and loss of appetite, fever, and anemia . Complications of Crohn's disease may include intestinal blockage, fistulas , anal fissures , ulcers, malnutrition, and inflammation in other areas of the body. Crohn's disease can occur in people of all age groups but is most often diagnosed in young adults. The exact cause is unknown, but is thought to be due from a combination of certain genetic variations, changes in the immune system , and the presence of bacteria in the digestive tract. Many of the major genes related to Crohn disease, including NOD2 , ATG16L1 , IL23R , and IRGM , are involved in immune system function. The disease is not inherited but it appears to run in some families because in about 15% of the cases the disease is present in more than one relative. Treatment is aimed at relieving symptoms and reducing inflammation, and may include diet and medication, but some people require surgery. Surgery often involves removal of the diseased segment of bowel (resection), the two ends of healthy bowel are then joined together (anastomosis). In about 30% of people who have surgery for Crohn's disease symptoms may come back within three years and up to 60% will have recurrence within ten years.

MedlinePlus : 42 Crohn's disease causes inflammation of the digestive system. It is one of a group of diseases called inflammatory bowel disease. Crohn's can affect any area from the mouth to the anus. It often affects the lower part of the small intestine called the ileum. The cause of Crohn's disease is unknown. It may be due to an abnormal reaction by the body's immune system. It also seems to run in some families. It most commonly starts between the ages of 13 and 30. The most common symptoms are pain in the abdomen and diarrhea. Other symptoms include Bleeding from the rectum Weight loss Fever Your doctor will diagnose Crohn's disease with a physical exam, lab tests, imaging tests, and a colonoscopy. Crohn's can cause complications, such as intestinal blockages, ulcers in the intestine, and problems getting enough nutrients. People with Crohn's can also have joint pain and skin problems. Children with the disease may have growth problems. There is no cure for Crohn's. Treatment can help control symptoms, and may include medicines, nutrition supplements, and/or surgery. Some people have long periods of remission, when they are free of symptoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Wikipedia : 74 Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the... more...

Related Diseases for Crohn's Disease

Diseases related to Crohn's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2160)
# Related Disease Score Top Affiliating Genes
1 ileocolitis 33.4 NOD2 DUOX2 ATG16L1
2 inflammatory bowel disease 1 33.1 SLC22A5 SLC22A4 NOD2 IRGM IL23R ATG16L1
3 inflammatory bowel disease 25, autosomal recessive 32.9 IL10RB IL10RA
4 inflammatory bowel disease 32.8 SLC22A5 SLC22A4 SLC11A1 NOD2 LACC1 ITGA4
5 ulcerative colitis 32.4 NOD2 LACC1 IRGM IRF5 IL23R IL10RB
6 colitis 32.2 NOD2 LACC1 IRGM IRF5 IL23R IL10RB
7 spondyloarthropathy 1 31.8 NOD2 IL23R HP
8 sclerosing cholangitis 31.7 NOD2 HP HLA-DRB1
9 sarcoidosis 1 31.6 SLC11A1 NOD2 IL12RB2 HLA-DRB1
10 cholangitis 31.6 NOD2 IL12RB2 HP HLA-DRB1
11 celiac disease 1 31.5 NOD2 IL23R IL18RAP HP HLA-DRB1 ATG16L1
12 inflammatory bowel disease 5 31.4 SLC22A5 SLC22A4 NOD2 IRGM IL23R IL18RAP
13 arthritis 31.3 SLC11A1 NOD2 LACC1 IRF5 HLA-DRB1
14 pulmonary tuberculosis 31.2 SLC11A1 HP HLA-DRB1
15 inflammatory bowel disease 19 31.1 NOD2 IRGM
16 rheumatoid arthritis 31.1 SLC22A4 SLC11A1 LACC1 IRF5 IL23R HP
17 spondylarthropathy 31.0 NOD2 HP
18 leprosy 3 30.9 SLC11A1 NOD2 LACC1 IRGM IL23R IL12RB2
19 inflammatory bowel disease 3 30.9 NOD2 IL23R
20 inflammatory bowel disease 2 30.9 NOD2 ATG16L1
21 inflammatory bowel disease 6 30.9 NOD2 IL23R ATG16L1
22 inflammatory bowel disease 18 30.7 NOD2 ATG16L1
23 behcet syndrome 30.6 NOD2 IL23R IL12RB2 HLA-DRB1
24 post-transplant lymphoproliferative disease 30.0 SLC11A1 IL10RA
25 relapsing-remitting multiple sclerosis 29.9 ITGA4 IL23R HLA-DRB1
26 lymphoproliferative syndrome, x-linked, 2 29.9 NOD2 IL10RA
27 thoraco abdominal enteric duplication 12.5
28 gastroduodenal crohn's disease 12.5
29 crohn's disease of the esophagus 12.4
30 obsolete: azathioprine dose selection in the treatment of crohn disease, leukemia and in transplantation 12.3
31 obsolete: mercaptopurine dose selection in the treatment of crohn disease, leukemia and in transplantation 12.3
32 trichohepatoenteric syndrome 1 12.3
33 enteric pattern testicular yolk sac tumor 12.2
34 diarrhea 4, malabsorptive, congenital 11.7
35 melkersson-rosenthal syndrome 11.7
36 irritable bowel syndrome 11.6
37 orofacial granulomatosis 11.6
38 ileitis 11.6
39 diarrhea 11.6
40 hirschsprung disease 1 11.5
41 short bowel syndrome 11.5
42 pyoderma gangrenosum 11.5
43 rickets 11.5
44 colorectal cancer 11.5
45 coccidiosis 11.5
46 campylobacteriosis 11.5
47 epidermolysis bullosa acquisita 11.5
48 keratomalacia 11.5
49 aspiration pneumonia 11.5
50 skin tag 11.5

Comorbidity relations with Crohn's Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Inflammatory Bowel Disease 1
Intestinal Obstruction Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Crohn's Disease:



Diseases related to Crohn's Disease

Symptoms & Phenotypes for Crohn's Disease

UMLS symptoms related to Crohn's Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Crohn's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ABCB1 ATG16L1 HP IL10RA IL10RB IL12RB2
2 digestive/alimentary MP:0005381 9.91 ABCB1 ATG16L1 IL10RA IL10RB IL12RB2 IL23R
3 homeostasis/metabolism MP:0005376 9.8 ABCB1 ATG16L1 DUOX2 HP IL10RA IL10RB
4 immune system MP:0005387 9.47 ABCB1 ATG16L1 HP IL10RA IL10RB IL12RB2

Drugs & Therapeutics for Crohn's Disease

Drugs for Crohn's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Prucalopride Approved Phase 4 179474-81-8
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Copper Approved, Investigational Phase 4 7440-50-8 27099
5
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
6
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
7
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
8
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
9
Dimenhydrinate Approved Phase 4 523-87-5 441281
10
Linaclotide Approved Phase 4 851199-59-2 65351
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
14
Caffeine Approved Phase 4 58-08-2 2519
15
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
16
Losartan Approved Phase 4 114798-26-4 3961
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
18
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Vancomycin Approved Phase 4 1404-90-6 441141 14969
22
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
23
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
24
Ustekinumab Approved, Investigational Phase 4 815610-63-0
25
Apixaban Approved Phase 4 503612-47-3 10182969
26
tannic acid Approved Phase 4 1401-55-4
27
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
28
leucovorin Approved Phase 4 58-05-9 6006 143
29
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
30
Certolizumab pegol Approved Phase 4 428863-50-7
31
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
33
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
35 Tocotrienol Investigational Phase 4 6829-55-6
36 Antioxidants Phase 4
37 Tocopherols Phase 4
38 Tocotrienols Phase 4
39 Hematinics Phase 4
40 Dopamine Uptake Inhibitors Phase 4
41 Antidepressive Agents Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 calcium channel blockers Phase 4
44 Vitamin K 1 Phase 4
45 Diphosphonates Phase 4
46 Polyethylene glycol 3350 Phase 4
47 Histamine H1 Antagonists Phase 4
48 Iron Supplement Phase 4
49 glutamine Phase 4
50 Ferric Oxide, Saccharated Phase 4

Interventional clinical trials:

(show top 50) (show all 1563)
# Name Status NCT ID Phase Drugs
1 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
2 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
3 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
4 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
5 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
6 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
7 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
8 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
9 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
10 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
11 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
12 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Unknown status NCT01817426 Phase 4 Infliximab
13 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
14 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
15 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
16 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
17 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
18 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
19 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
20 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
21 SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Completed NCT02199626 Phase 4
22 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
23 Vitamin D and Immunomodulation: Effects in Crohn's Disease Completed NCT01369667 Phase 4
24 Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study) Completed NCT02148718 Phase 4
25 Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission Completed NCT01792388 Phase 4
26 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
27 A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone. Completed NCT01596894 Phase 4 Azithromycin + Metronidazole;Metronidazole
28 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
29 A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies Completed NCT00280956 Phase 4 natalizumab
30 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
31 A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease Completed NCT01183845 Phase 4
32 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
33 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
34 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
35 Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease Completed NCT00546546 Phase 4 early immunosuppressants (azathioprine, methotrexate)
36 A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease Completed NCT01442025 Phase 4 Infliximab;Infliximab;Infliximab
37 The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux Completed NCT00554710 Phase 4 infliximab+azathioprine;methylprednisolone or budesonide
38 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
39 A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease Completed NCT01030809 Phase 4
40 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study) Completed NCT01181765 Phase 4
41 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
42 Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tbl. 500 mg in Children With Crohn´s Disease Completed NCT00225810 Phase 4 Crohn's Disease
43 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
44 Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease Completed NCT00588653 Phase 4
45 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
46 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
47 A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE) Completed NCT02630966 Phase 4 Vedolizumab;Placebo
48 Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%
49 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
50 Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab Completed NCT01556672 Phase 4 Adalimumab

Search NIH Clinical Center for Crohn's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Azathioprine
Cholecalciferol
natalizumab
Opium
OPIUM ALKALOIDS HYDROCHLORIDE
OPIUM, POWDERED
paregoric
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Crohn's Disease cell therapies at LifeMap Discovery.

Genetic Tests for Crohn's Disease

Anatomical Context for Crohn's Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Crohn's Disease:

19
Intestine

MalaCards organs/tissues related to Crohn's Disease:

40
Colon, T Cells, Bone, Small Intestine, Testes, Skin, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Crohn's Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Crohn's Disease

Articles related to Crohn's Disease:

(show top 50) (show all 33361)
# Title Authors PMID Year
1
Association of Glutathione S-Transferase M1 null genotype with inflammatory bowel diseases: A systematic review and meta-analysis. 61 42
31689810 2019
2
A novel surgical predictive model for Chinese Crohn's disease patients. 61 42
31725605 2019
3
Management of Crohn's disease: summary of updated NICE guidance. 61 42
31676715 2019
4
Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study. 61
31851083 2020
5
Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature. 61
31851086 2020
6
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. 61
31834046 2020
7
Defying Occam's Razor: Colonic Luminal Endometriosis in an Adolescent With Crohn's Disease. 61
31771925 2020
8
Anorectal Cancer in Crohn's Disease Has a Poor Prognosis Due to its Advanced Stage and Aggressive Histological Features: a Systematic Literature Review of Japanese Patients. 61
30474795 2020
9
Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014. 61
31092591 2020
10
Modulation of cytokine patterns and microbiome during pregnancy in IBD. 61
31167813 2020
11
Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. 61
31792136 2020
12
Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. 61
31142586 2020
13
A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's Disease. 61
31822515 2020
14
Crohn's disease in Israeli Jews of Ethiopian heritage-a case series. 61
31872266 2020
15
Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. 61
31915984 2020
16
Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. 61
31631340 2020
17
Parental Psychological Factors and Quality of Life of Children With Inflammatory Bowel Disease. 61
31978019 2020
18
Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. 61
31640916 2020
19
Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. 61
31782939 2020
20
Mannose-capped lipoarabinomannan-induced B10 cells decrease severity of dextran sodium sulphate-induced inflammatory bowel disease in mice. 61
31657484 2020
21
Do Patients With Inflammatory Bowel Disease Have a Higher Postoperative Risk of Venous Thromboembolism or Do They Undergo More High-risk Operations? 61
30169396 2020
22
Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review. 61
31267125 2020
23
Cultivated Escherichia coli diversity in intestinal microbiota of Crohn's disease patients and healthy individuals: Whole genome data. 61
31886370 2020
24
Primary Cutaneous Follicle Center Lymphoma in a 16-Year-old boy With Crohn Disease Exposed to Infliximab and Methotrexate. 61
31978035 2020
25
Magnetic Resonance in Crohn's Disease: Diagnosis, Disease Burden, and Classification. 61
31753235 2020
26
Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial. 61
32039987 2020
27
Nomogram to Predict Postoperative Intra-abdominal Septic Complications after Bowel Resection And Primary Anastomosis for Crohn's Disease. 61
32032204 2020
28
Histologically confirmed upper gastrointestinal Crohn's disease: is it rare or are we just not searching hard enough? 61
32019291 2020
29
Supplementary Anal Imaging by Magnetic Resonance Enterography in Patients with Crohn's Disease Not Suspected of Having Perianal Fistulas. 61
31352093 2020
30
Endoplasmic Reticulum Stress in Subepithelial Myofibroblasts Increases the TGF-β1 Activity That Regulates Fibrosis in Crohn's Disease. 61
32031621 2020
31
Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. 61
31641874 2020
32
Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. 61
31350718 2020
33
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis. 61
31839219 2020
34
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. 61
32024071 2020
35
Laparoscopy in Crohn Disease: Learning Curve and Current Practice. 61
30080737 2020
36
Magnetic Resonance in Crohn Disease: Imaging Biomarkers in Assessing Response to Therapy. 61
31753236 2020
37
Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn's disease treated with antitumor necrosis factor-alpha agents based on Parks' classification. 61
31851087 2020
38
Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn's disease. 61
32020185 2020
39
Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases. 61
32009281 2020
40
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. 61
32027523 2020
41
Lymphocyte-predominant Esophagitis: A Distinct and Likely Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis. 61
31651525 2020
42
Intake of dairy protein during pregnancy in IBD and risk of SGA in a Norwegian population-based mother and child cohort. 61
32013916 2020
43
Primary biliary cholangitis in patients with inflammatory bowel disease. 61
31171469 2020
44
Enhanced E. coli LF82 Translocation through the Follicle-associated Epithelium in Crohn's Disease is Dependent on Long Polar Fimbriae and CEACAM6 expression, and Increases Paracellular Permeability. 61
31393983 2020
45
Pancreatic anti-GP2 and anti-Saccharomyces cerevisiae antibodies in ruminants with paratuberculosis: A better understanding of the immunopathogenesis of Crohn's disease. 61
32035824 2020
46
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. 61
31711925 2020
47
Fragility index: how fragile is the data that support the American College of Gastroenterology guidelines for the management of Crohn's disease? 61
31851082 2020
48
Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics
. 61
31657711 2020
49
Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease. 61
31821976 2020
50
Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. 61
31859538 2020

Variations for Crohn's Disease

Copy number variations for Crohn's Disease from CNVD:

7 (show all 25)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19625 1 150839831 150840116 Deletion and duplication LCE3C Crohn''s disease
2 19631 1 150852910 150853198 Deletion and duplication LCE3B Crohn''s disease
3 71426 12 69818942 132349534 Copy number Crohn''s disease
4 112709 17 40930407 78774742 Copy number Crohn''s disease
5 139336 2 179004449 242951149 Copy number Crohn''s disease
6 194979 5 147200000 152100000 Low copy numbers IRGM Crohn''s disease
7 195288 5 149800000 152700000 Copy number Crohn''s disease
8 195354 5 150157836 180857866 Copy number Crohn''s disease
9 195374 5 150183562 180857866 Copy number Crohn''s disease
10 195384 5 150207878 150208422 Deletion IRGM Crohn''s disease
11 195385 5 150207878 150208422 Deletion and duplication IRGM Crohn''s disease
12 210788 6 31416574 170899992 Copy number Crohn''s disease
13 211338 6 32582950 170899992 Copy number Crohn''s disease
14 211384 6 32609209 170899992 Copy number Crohn''s disease
15 211736 6 336751 356443 Copy number IRF4 Crohn''s disease
16 230702 8 1 12700000 Copy number Crohn''s disease
17 241420 8 6200000 12700000 Copy number HBD-2 Crohn''s disease
18 241431 8 6200000 12700000 Duplication DEFB103 Crohn''s disease
19 241433 8 6200000 12700000 Duplication DEFB4 Crohn''s disease
20 241436 8 6200000 12700000 Duplication SPAG11 Crohn''s disease
21 241467 8 6200000 12700000 Low copy numbers Crohn''s disease
22 242030 8 6873390 6875823 Copy number Crohn''s disease
23 242532 8 7259842 7791647 Copy number DEFB4 Crohn''s disease
24 242534 8 7259842 7791647 Deletion and duplication DEFB4 Crohn''s disease
25 242535 8 7259842 7791647 Deletion and duplication HBD-2 Crohn''s disease

Expression for Crohn's Disease

LifeMap Discovery
Genes differentially expressed in tissues of Crohn's Disease patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 REG1A regenerating islet-derived 1 alpha Colon + 4.42 0.002
2 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 4.02 0.000
3 REG1B regenerating islet-derived 1 beta Colon + 3.99 0.008
4 LCN2 lipocalin 2 Colon + 3.90 0.000
5 REG3A regenerating islet-derived 3 alpha Colon + 3.74 0.026
6 CXCL11 chemokine (C-X-C motif) ligand 11 Colon + 3.70 0.016
7 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.60 0.000
8 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.50 0.004
9 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.49 0.029
10 S100A8 S100 calcium binding protein A8 Colon + 3.04 0.017
Search GEO for disease gene expression data for Crohn's Disease.

Pathways for Crohn's Disease

Pathways related to Crohn's Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 SLC11A1 NOD2 ITGA4 IRF5 IL23R IL18RAP
2
Show member pathways
12.97 NOD2 IRF5 IL23R IL18RAP IL12RB2 IL10RB
3
Show member pathways
12.33 IL23R IL18RAP IL10RB IL10RA
4
Show member pathways
12.07 IL23R IL12RB2 IL10RB IL10RA
5 11.99 NOD2 IL10RB IL10RA HLA-DRB1
6
Show member pathways
11.8 IL23R IL18RAP IL12RB2
7
Show member pathways
11.74 ITGA4 IL23R IL12RB2 IL10RB IL10RA
8
Show member pathways
11.71 IL18RAP IL12RB2 HLA-DRB1
9
Show member pathways
11.64 NOD2 IL23R IL18RAP IL12RB2 IL10RB HLA-DRB1
10
Show member pathways
11.63 ITGA4 IRGM IL10RB IL10RA HLA-DRB1
11 11.57 IL23R IL12RB2 IL10RB IL10RA
12 11.54 ITGA4 IL23R IL12RB2

GO Terms for Crohn's Disease

Cellular components related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 SLC22A5 SLC22A4 SLC11A1 NOD2 ITGA4 IRGM
2 cell surface GO:0009986 9.63 NOD2 ITGA4 HLA-DRB1 DUOX2 CEACAM6 ABCB1
3 plasma membrane GO:0005886 9.5 SLC22A5 SLC22A4 SLC11A1 NOD2 ITGA4 IRGM
4 apical plasma membrane GO:0016324 9.35 SLC22A5 SLC22A4 DUOX2 CEACAM6 ABCB1

Biological processes related to Crohn's Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.98 NOD2 IRGM IRF5 IL23R HLA-DRB1
2 defense response to bacterium GO:0042742 9.86 SLC11A1 NOD2 IRGM HP
3 inflammatory response GO:0006954 9.85 SLC11A1 IRGM IL23R IL18RAP IL10RB
4 defense response to Gram-negative bacterium GO:0050829 9.74 SLC11A1 IRGM IL23R
5 response to lipopolysaccharide GO:0032496 9.73 SLC11A1 IL23R IL12RB2 IL10RA
6 defense response GO:0006952 9.67 NOD2 IRGM HP DUOX2
7 response to interferon-gamma GO:0034341 9.59 SLC11A1 IL23R
8 positive regulation of interleukin-17 production GO:0032740 9.58 NOD2 IL23R
9 response to muramyl dipeptide GO:0032495 9.55 NOD2 IRF5
10 interferon-gamma production GO:0032609 9.54 IL18RAP IL12RB2
11 detection of bacterium GO:0016045 9.52 NOD2 HLA-DRB1
12 positive regulation of T-helper 1 type immune response GO:0002827 9.51 SLC11A1 IL23R
13 positive regulation of interferon-gamma production GO:0032729 9.5 SLC11A1 IL23R IL12RB2
14 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.49 NOD2 IRGM
15 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.48 SLC11A1 NOD2
16 carnitine transport GO:0015879 9.4 SLC22A5 SLC22A4
17 protein lipidation involved in autophagosome assembly GO:0061739 9.26 IRGM ATG16L1
18 quaternary ammonium group transport GO:0015697 9.16 SLC22A5 SLC22A4
19 cytokine-mediated signaling pathway GO:0019221 9.1 IRF5 IL23R IL12RB2 IL10RB IL10RA DUOX2
20 carnitine transmembrane transport GO:1902603 8.96 SLC22A5 SLC22A4

Molecular functions related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transporter activity GO:0005215 9.5 SLC22A5 SLC22A4 ABCB1
2 CARD domain binding GO:0050700 9.4 NOD2 IRGM
3 xenobiotic transmembrane transporter activity GO:0042910 9.37 SLC22A5 ABCB1
4 quaternary ammonium group transmembrane transporter activity GO:0015651 9.26 SLC22A5 SLC22A4
5 carnitine transmembrane transporter activity GO:0015226 9.16 SLC22A5 SLC22A4
6 interleukin-10 receptor activity GO:0004920 8.96 IL10RB IL10RA
7 cytokine receptor activity GO:0004896 8.92 IL23R IL12RB2 IL10RB IL10RA

Sources for Crohn's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....